# Junta clínica — PT-pseudo_3b6ea1920967 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_3b6ea1920967",
  "pid": "PT-pseudo_3b6ea1920967",
  "task": 1,
  "psa": 6.5,
  "age": 64,
  "months": 3,
  "pirads": "4",
  "psad": 0.11,
  "psav": 1.22,
  "psap": 4.5,
  "vol": 59.14,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.7465537,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 6.5 ng/mL. PI-RADS 4. PSAD 0.11. Prostate volume 59 mL. csPCa 0.75.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "70 kg",
    "height": "174 cm",
    "bmi": "23.1",
    "bp": "146/61 mmHg",
    "hr": "63 bpm",
    "smoking": "Ex-smoker (38 pack-yr, quit 2007)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "11 Jan 2025",
  "enc_ref": "Dr. K. Bakker (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical assessment required due to a prior prostate cancer diagnosis coupled with a recent PSA increase to 6.5 ng/mL."
    },
    {
      "s": "History",
      "t": "A 64-year-old retired primary school teacher initially came to medical attention for an incidental PSA rise in early 2023 and has since remained under surveillance after his first positive biopsy. He is widowed and shares his home with a long-term partner, enjoying an active routine that features weekend hiking alongside moderate alcohol intake of roughly four units weekly. He reports moderate lower urinary tract symptoms scoring 13 on the IPSS, while explicitly denying hematuria, bone pain, or unexplained weight loss. His smoking history includes 38 pack-years, having ceased consumption in 2007. He maintains a residence situated over ninety minutes from the clinic and has expressed a preference for telephone follow-ups when clinically suitable, having recently finished a baseline memory clinic screening and a standard audiology assessment."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland presents as symmetrically enlarged without palpable nodules. General examination remains unremarkable, with stable vital signs, clear lung fields, and a regular cardiac rhythm. Peripheral lymphadenopathy and abdominal masses are notably absent."
    }
  ],
  "occupation": "retired primary school teacher",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Audiology — hearing test",
    "Memory clinic — baseline screening"
  ],
  "alcohol": "4 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 13/35 (moderate LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Erasmus MC",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3b6ea1920967
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 64-year-old male
  - PSA: 6.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.11 ng/mL²
  - PSA velocity: 1.22 ng/mL/yr
  - Prior PSA: 4.5 ng/mL
  - Prostate volume: 59.14 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7465537 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 6.5 ng/mL. PI-RADS 4. PSAD 0.11. Prostate volume 59 mL. csPCa 0.75.

Vitals: weight 70 kg, height 174 cm, BMI 23.1, BP 146/61 mmHg, HR 63 bpm. Smoking: Ex-smoker (38 pack-yr, quit 2007).

Chief complaint: Clinical assessment required due to a prior prostate cancer diagnosis coupled with a recent PSA increase to 6.5 ng/mL.

History: A 64-year-old retired primary school teacher initially came to medical attention for an incidental PSA rise in early 2023 and has since remained under surveillance after his first positive biopsy. He is widowed and shares his home with a long-term partner, enjoying an active routine that features weekend hiking alongside moderate alcohol intake of roughly four units weekly. He reports moderate lower urinary tract symptoms scoring 13 on the IPSS, while explicitly denying hematuria, bone pain, or unexplained weight loss. His smoking history includes 38 pack-years, having ceased consumption in 2007. He maintains a residence situated over ninety minutes from the clinic and has expressed a preference for telephone follow-ups when clinically suitable, having recently finished a baseline memory clinic screening and a standard audiology assessment.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland presents as symmetrically enlarged without palpable nodules. General examination remains unremarkable, with stable vital signs, clear lung fields, and a regular cardiac rhythm. Peripheral lymphadenopathy and abdominal masses are notably absent.

Patient info: retired primary school teacher; Widowed; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Hiking on weekends; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Memory clinic — baseline screening.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.56
  uncertainty  +/- 0.13 epistemic (95% band 0.31-0.82); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 4, PSA 6.5, PSAD 0.11, age 64, DRE Normal -> DEFER (uncertain). He wrote: "Need initial ISUP grade and MRI in men on active surveillance."
  2. distance 0.36: PI-RADS 4, PSA 5.3, PSAD 0.092, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 65 years old patient"
  3. distance 0.89: PI-RADS 4, PSA 6.8, PSAD 0.2, age 62, DRE Normal -> DEFER (borderline). He wrote: "All depends if the lesion has grown in size since 2024. If stable no biopsy , if increased in size I will do a biopsy."

PRECEDENT: DEFER. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: comorbidity=noted, pirads=important, bx=important, age=important, psad=noted, fh=noted, vol=noted, psa=noted, dre=noted.
HOW SURE HE USUALLY IS: uncertain.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline makes the decision dependent on the MRI findings, which are not yet fully established. The precedent suggests deferral in the case with an identical panel, indicating that the panel variables alone do not settle the decision.

WHAT WE STILL NEED
The prior biopsy status is known as 'Positive', which is a fact that the guideline makes it decide.
The prior biopsy status is 'Positive', which is a fact that the guideline makes it decide.
The documented grade of the prior biopsy is not known, which is a fact that the guideline makes it decide.
The number and dates of biopsy sessions are not known, which is a fact that the guideline makes it decide.
Whether he is on a surveillance protocol with a confirmatory biopsy due is not known, which is a fact that the guideline makes it decide.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the grade and history of the prior biopsy to determine the next step according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What was the prior biopsy grade (Gleason/ISUP), the number and dates of biopsy sessions, and the surveillance protocol status?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the ISUP grade of the prior positive biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone is "spanning roughly 11 mm along its longest axis" in the "left mid peripheral zone". Extraprostatic extension is "no evidence of extracapsular extension or seminal vesicle invasion". Comparison against an earlier study is "Re-evaluation of prior prostate cancer diagnosis".
psa_trend
The serial PSA value trend is "rising" with values: "Jan 2023: 2.1", "Sep 2023: 3.1", "May 2024: 4.5", "Jan 2025: 6.5".
previous_notes
The prior biopsy grade is "not recorded". The number and dates of biopsy sessions is "not recorded". The surveillance protocol status is "triggered this urology referral for clinical assessment".

WHAT I DID NOT OPEN
I did not open the laboratory_results or the family-history anamnesis because the required information regarding the prior biopsy grade and surveillance protocol status was found in the previous_notes.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
The serial PSA value trend is "rising" with values: "Jan 2023: 2.1", "Sep 2023: 3.1", "May 2024: 4.5", "Jan 2025: 6.5".
Findings that argue AGAINST sampling this patient now:
The prior biopsy grade is "not recorded".
The number and dates of biopsy sessions is "not recorded".
The surveillance protocol status is "triggered this urology referral for clinical assessment".

WHERE THIS LEANS
The rising PSA trend and the unknown prior biopsy grade and surveillance status create significant uncertainty, leaning towards further investigation.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.50 ng/mL over 4 points spanning 24 months; velocity +2.19 ng/mL per year; doubling time about 15 months.
PROJECTION at 6 months: 9.4 ng/mL, conformal 95% band 2.7-32.6.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.62
  uncertainty  +/- 0.11 epistemic (95% band 0.40-0.84), of which 0.01 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.56  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.62  ('supports' tier, fusion_nolab)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.10  (identical panel in the series)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: NO BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-FUSION. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: uncertain. Weights it expects: comorbidity=noted, pirads=important, bx=important, age=important, psad=noted, fh=noted, vol=noted, psa=noted, dre=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—did not fully answer the moderator's questions. Specifically, the previous_notes stated the prior biopsy grade and surveillance status were "not recorded" and "triggered this urology referral for clinical assessment," respectively.

ALIGNMENT WITH THE PANEL
The panel protocol concluded NO BIOPSY based on the EXPERT-LIBRARY precedent due to an identical panel. The retrieved evidence, particularly the rising PSA trend, leans towards further investigation, which contradicts the panel's final decision.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the ISUP grade of the prior positive biopsy? This remains unanswered, as the previous_notes state the grade is "not recorded."
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? This remains unanswered, as the previous_notes state the number/dates are "not recorded" and the status is "triggered this urology referral for clinical assessment."

WHAT CARRIES WEIGHT, AND WHY
The serial PSA trend (rising from 2.1 to 6.5 ng/mL) is highly relevant as it indicates disease progression. The unknown prior biopsy grade and surveillance status are critical because the EAU guideline explicitly states the decision depends on this prior biopsy status and grade.

MY SUGGESTION TO THE CHAIR
Given the rising PSA trend and the lack of documented prior biopsy information, the guideline suggests further investigation to confirm progression. I suggest a biopsy to establish the current histological status.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: uncertain)

The panel protocol concluded no biopsy based on an identical precedent in the labelled series, which is the primary factor. Although the rising PSA trend and the lack of documented prior biopsy grade create uncertainty, no retrieved finding overturned this decision. The evidence converged on the precedent, suggesting deferral pending further clinical assessment.

What carried weight: comorbidity=noted, pirads=important, bx=important, age=important, psad=noted, vol=noted, psa=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
